Skip to main content
. 2017 May 8;8:15111. doi: 10.1038/ncomms15111

Figure 1. Effect of hepatic p53 down-regulation on liver steatosis.

Figure 1

(a) p53 protein levels in the liver after a tail vein injection of an associate adenovirus serotype 8 (AAV8) expressing either GFP or Cre in p53floxed mice fed a standard diet (STD) (n=7 per group). Effects of the liver-specific silencing of p53 on (b) in hematoxylin-eosin (upper panel) and oil red O staining (lower panel) of mice liver sections (n=3 per group); (c) total liver TG content, serum AST, ALT and TG levels (n=8 AAV8-GFP and 10 AAV8-Cre mice); (d) liver protein levels of FAS, pJNK/JNK, pIRE/IRE, XBP1s, pPERK, peIF2α/eIF2α, cleaved caspase 3, cleaved caspase 7, ApoB100 and ApoB48; (e) mRNA expression of CPT1, ACADM, ACADL and FATP2; (f) serum ketone bodies; (g) glucose and (h) insulin tolerance test (n=8 AAV8-GFP and 10 AAV8-Cre mice). The values of AAV8 GFP mice were always normalized to 100% (n=7 per group). Protein GAPDH or transferrin levels were used to normalize protein levels. Dividing lines indicate splicings in the same gel. Uncropped blots of this Figure accompanied by the location of molecular weight markers are shown in Supplementary Fig. 10. Data are presented as mean±standard error mean (s.e.m.). Statistical significance, *P<0.05 and **P<0.01, was tested using Student t-test comparing AAV8-GFP and AAV8-Cre mice.